NCT04659109View on ClinicalTrials.gov

Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19

PHASE2CompletedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

December 16, 2020

Primary Completion Date

August 6, 2021

Study Completion Date

August 6, 2021

Conditions

SARS-CoV InfectionAcute Respiratory Distress SyndromeCOVID-19ARDS

Interventions

DRUG

glenzocimab

IV administration as a sterile product

DRUG

Placebo

IV administration

Trial Locations (1)

67091

Hôpital de Hautepierre, Strasbourg

Sponsors

Lead Sponsor

Acticor Biotech

All Listed Sponsors

lead

Acticor Biotech

INDUSTRY

NCT04659109 - Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19 | Biotech Hunter | Biotech Hunter